D. Danielle Kamato

Neratinib reduces atherosclerosis by inhibiting ASK1-mediated endothelial inflammation, showing potential as a repurposed drug for vascular disease.

This study shows halofuginone, an FDA-approved drug, reduces obesity in mice by increasing FGF21 and GDF15 levels, improving metabolic health.